[Use of recombinant activated factor VII]

Area of Science:

• Hematology
• Pharmacology
• Biotechnology

Background:

• Hemostasis relies on activated factor VII (FVIIa) binding to tissue factor (TF), a small fraction of total FVII.
• Recombinant activated factor VII (rFVIIa) has over a decade of use in managing hemostatic disorders.

Purpose of the Study:

• To review the efficacy and applications of rFVIIa in treating diverse bleeding conditions.
• To highlight rFVIIa's potential as a universal hemostatic agent.

Main Methods:

• Review of clinical data and therapeutic applications of rFVIIa.
• Analysis of rFVIIa's mechanism of action in hemostasis.

Main Results:

• rFVIIa demonstrates high efficacy (76-84%) in treating life-threatening hemorrhagic states, including hemophilia.
• Successful use in congenital factor VII deficiency, liver diseases, anticoagulant overdose, and thrombocytopenia.
• Effective in managing hemophilia A and B with inhibitors and uncontrollable hemorrhages.

Conclusions:

• rFVIIa is a valuable therapeutic agent for a wide spectrum of hemostatic disorders.
• Its broad applicability suggests a role as a universal hemostatic drug.